MANGOCEUTICALS INC. -

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

03 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

01 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

15 Aug 2024 08:25:00 By Nasdaq GlobeNewswire

MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent

13 Aug 2024 15:00:00 By Nasdaq GlobeNewswire

MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide

09 Aug 2024 07:15:00 By Nasdaq GlobeNewswire

MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology

24 Jul 2024 07:15:00 By Nasdaq GlobeNewswire

Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access

18 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

16 Jul 2024 07:20:00 By Nasdaq GlobeNewswire

MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

12 Jul 2024 12:30:00 By Nasdaq GlobeNewswire

MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets

11 Jul 2024 07:15:00 By Nasdaq GlobeNewswire

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

06 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

04 Jun 2024 15:00:00 By Nasdaq GlobeNewswire

MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

04 Jun 2024 07:00:01 By Nasdaq GlobeNewswire

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets

28 May 2024 07:30:00 By Nasdaq GlobeNewswire

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

23 May 2024 07:30:00 By Nasdaq GlobeNewswire

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

21 May 2024 07:30:00 By Nasdaq GlobeNewswire

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

16 May 2024 15:40:00 By Nasdaq GlobeNewswire

Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care

25 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

12 Apr 2024 07:45:00 By Nasdaq GlobeNewswire